CDMOs offering Downstream Processing with Cell Therapy
14 published
14 published CDMOs match Downstream Processing and Cell Therapy.
Locations in this set include United States, United Kingdom, China, Japan, Denmark, and Canada.
Capabilities that show up most often in this set: Upstream Processing, CMC Analytical Development, Cell Therapy Manufacturing, Process Development, and Technology Transfer.
Matching companies
AGC BiologicsGlobal CDMO offering development and manufacturing for protein expression biologics, pDNA, mRNA, viral vectors (AAV, LVV, RVV), and genetically engineered cells with scale-out manufacturing capabilities.
Andelyn BiosciencesCDMO specializing in plasmid DNA and AAV viral vector manufacturing for cell and gene therapy, with digital-first platform emphasizing data integrity and collaboration.
Artis BioSolutionsIntegrated CDMO platform combining proprietary enzymatic synthetic DNA production with advanced therapy development and GMP manufacturing for mRNA, gene editing, viral vectors, cell therapies, and vaccines.
Boston Institute of Biotechnology, LLCFull-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.
CatalentGlobal CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
Cell and Gene Therapy CatapultUK-based innovation and manufacturing support organization for cell and gene therapies, offering infrastructure, expertise, and collaboration across the ATMP lifecycle.
Charles River LaboratoriesCharles River Laboratories provides contract research, development, and manufacturing services across the full drug discovery and development continuum, supporting 80% of FDA-approved drugs over the past five years.
FUJIFILM BiotechnologiesCDMO partner offering end-to-end biologics development and manufacturing from pre-clinical through commercialization, with expertise in cell culture, microbial fermentation, cell and gene therapy, and cGMP manufacturing across US and European facilities.
GenezenViral vector CDMO specializing in AAV, lentiviral, and retroviral manufacturing for gene and cell therapies, with cGMP facilities in Indiana and Massachusetts supporting preclinical through commercial-scale production.
Lonza Cell & Gene TechnologiesLonza is the world's leading CDMO, founded in Switzerland in 1897, serving the healthcare industry with integrated offerings for contract development and manufacturing of therapies across multiple modalities.
National ResilienceEnd-to-end CDMO specializing in complex modalities including cell, gene, and RNA-based therapies with North American manufacturing facilities and development capabilities.
Oxford BiomedicaGlobal viral vector CDMO with 30 years of expertise in lentivirus, AAV, and adenovirus manufacturing. Provides end-to-end development and GMP-compliant manufacturing services from preclinical through commercial launch for cell and gene therapy programs.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/downstream-processing/cell-therapy.md